Q4 Earnings Estimate for CRVS Issued By HC Wainwright

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities researchers at HC Wainwright issued their Q4 2024 earnings per share estimates for shares of Corvus Pharmaceuticals in a report released on Thursday, January 2nd. HC Wainwright analyst S. Lee forecasts that the company will post earnings of ($0.12) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2029 earnings at $0.49 EPS.

A number of other research analysts have also recently issued reports on the stock. LADENBURG THALM/SH SH raised their price target on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Oppenheimer boosted their price target on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Finally, Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Trading Up 7.4 %

Corvus Pharmaceuticals stock opened at $5.83 on Friday. Corvus Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $10.00. The firm has a market cap of $374.62 million, a price-to-earnings ratio of -6.27 and a beta of 1.07. The stock has a fifty day simple moving average of $7.67 and a two-hundred day simple moving average of $5.29.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Several large investors have recently bought and sold shares of CRVS. Nwam LLC purchased a new stake in Corvus Pharmaceuticals during the 3rd quarter valued at about $53,000. XTX Topco Ltd purchased a new stake in Corvus Pharmaceuticals in the third quarter valued at $74,000. Virtu Financial LLC acquired a new stake in Corvus Pharmaceuticals in the 3rd quarter valued at approximately $83,000. Oppenheimer & Co. Inc. purchased a new position in shares of Corvus Pharmaceuticals during the third quarter worth $89,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at $44,000. 46.64% of the stock is currently owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.